Results 151 to 160 of about 16,016 (250)

AMA‐Positive Cholestasis in Celiac Disease: Why Primary Biliary Cholangitis Should Not Be Excluded by Biopsy Alone

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT In celiac disease patients with AMA‐M2 positivity, cholestatic enzymes, pruritus, and fibrosis, early primary biliary cholangitis should remain under longitudinal surveillance; nondiagnostic biopsy alone should not exclude autoimmune cholestatic overlap.
Muhammad Abdullah Awan
wiley   +1 more source

REVERSIBILITY OF VITAMIN E DEFICIENCY NEUROLOGIC SYNDROME DURING CHRONIC CHILDHOOD CHOLESTASIS [PDF]

open access: bronze, 1984
Ronald J. Sokol   +5 more
openalex   +1 more source

Epigenetic Perspectives on Maternal Gut Microbiota's Impact on Embryonic and Fetal Development

open access: yesComprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how maternal health and nutrition shape gut microbiota via epigenetics to regulate embryonic development. It highlights microbiota‐embryo interactions, disruption by prenatal chemical exposures, and personalized nutrition for disease prevention, offering novel insights and therapeutic targets.
Shoulong Xu   +6 more
wiley   +1 more source

Drug-induced hepatic cholestasis in the ICU: a case-control study [PDF]

open access: gold, 2010
David Williamson   +5 more
openalex   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra   +4 more
wiley   +1 more source

Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract Neurodegenerative Langerhans cell histiocytosis (ND‐LCH) is a severe and debilitating complication of LCH with no effective treatment. In this study, we assessed the efficacy of MAPK inhibitors (MAPKi) in a large cohort of children with ND‐LCH. We included pediatric patients with ND‐LCH who received MAPKi between 2013 and 2025.
Francesco Pegoraro   +38 more
wiley   +1 more source

Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five‐Year Single‐Center Cross‐Sectional Study

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Objectives Immune thrombocytopenia (ITP) during pregnancy presents unique management challenges. This study represents the first analysis of ITP outcomes during pregnancy in Qatar, aiming to assess maternal and neonatal outcomes at a tertiary care center.
Sara Elkorashi   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy